NYSE · AHealthcareLab Analytical Instruments

Agilent Technologies financials

$175.21+1.40%

Close Sep 28, 2026 · split-adjusted

Quarterly Annual

Revenue

1.69BQ4 '23

1.66BQ1 '24

1.57BQ2 '24

1.58BQ3 '24

1.70BQ4 '24

1.68BQ1 '25

1.67BQ2 '25

1.74BQ3 '25

1.86BQ4 '25

1.80BQ1 '26

1.83BQ2 '26

1.88BQ3 '26

Net income

475.0MQ4 '23

348.0MQ1 '24

308.0MQ2 '24

282.0MQ3 '24

351.0MQ4 '24

318.0MQ1 '25

215.0MQ2 '25

336.0MQ3 '25

434.0MQ4 '25

305.0MQ1 '26

339.0MQ2 '26

362.0MQ3 '26

Income statement & cash flow

Quarter	Q3 '26 Jul 31	Q2 '26 Apr 30	Q1 '26 Jan 31	Q4 '25 Oct 31	Q3 '25 Jul 31	Q2 '25 Apr 30	Q1 '25 Jan 31	Q4 '24 Oct 31	Q3 '24 Jul 31	Q2 '24 Apr 30	Q1 '24 Jan 31	Q4 '23 Oct 31
Revenue	$1.88B	$1.83B	$1.80B	$1.86B	$1.74B	$1.67B	$1.68B	$1.70B	$1.58B	$1.57B	$1.66B	$1.69B
Gross profit	$1.04B	$990.0M	$946.0M	$990.0M	$888.0M	$866.0M	$899.0M	$916.0M	$855.0M	$856.0M	$908.0M	$915.0M
Gross margin	55.5%	54.0%	52.6%	53.2%	51.1%	51.9%	53.5%	53.9%	54.2%	54.4%	54.8%	54.2%
Operating income	$444.0M	$399.0M	$353.0M	$443.0M	$360.0M	$300.0M	$376.0M	$408.0M	$333.0M	$363.0M	$384.0M	$408.0M
Net income	$362.0M	$339.0M	$305.0M	$434.0M	$336.0M	$215.0M	$318.0M	$351.0M	$282.0M	$308.0M	$348.0M	$475.0M
Net margin	19.3%	18.5%	17.0%	23.3%	19.3%	12.9%	18.9%	20.6%	17.9%	19.6%	21.0%	28.1%
Diluted EPS	$1.28	$1.20	$1.07	$1.53	$1.18	$0.75	$1.11	$1.23	$0.97	$1.05	$1.18	$1.61
EBITDA	$510.0M	$466.0M	$420.0M	$514.0M	$432.0M	$373.0M	$448.0M	$477.0M	$396.0M	$426.0M	$446.0M	$408.0M
Operating cash flow	$519.0M	$277.0M	$268.0M	$545.0M	$362.0M	$221.0M	$431.0M	$481.0M	$452.0M	$333.0M	$485.0M	$516.0M
Free cash flow	$439.0M	$201.0M	$175.0M	$452.0M	$259.0M	$107.0M	$334.0M	$388.0M	$360.0M	$230.0M	$395.0M	$432.0M
Diluted shares	283.0M	283.0M	284.0M	283.0M	285.0M	285.0M	287.0M	286.0M	291.0M	293.0M	294.0M	295.0M

Balance sheet

Period end	Jul 31	Apr 30	Jan 31	Oct 31	Jul 31	Apr 30
Cash & equivalents	$1.76B	$1.81B	$1.76B	$1.79B	$1.53B	$1.49B
Short-term investments	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total debt	$3.95B	$3.35B	$3.35B	$3.35B	$3.41B	$3.50B
Total assets	$13.97B	$13.06B	$12.81B	$12.73B	$12.23B	$12.16B
Total liabilities	$6.60B	$5.94B	$5.91B	$5.99B	$5.86B	$6.02B
Shareholders' equity	$7.36B	$7.12B	$6.91B	$6.74B	$6.37B	$6.14B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology